welcome to the website of the

17th St.Gallen International Breast Cancer Conference 2021

17 – 21 March 2021, online worldwide

 

The scientific chairs and the organizers invited you to our first ever virtual 17th St.Gallen International Breast Cancer Conference from 17 to 21 March 2021! Experts of all major cooperative groups and centres worldwide actively engaged in basic and clinical research as well as in clinical management of patients with breast cancer presented their latest data, critically reviewed by leading specialists in the field, culminated in the famous St.Gallen International Breast Cancer Consensus Session.

We want to take this opportunity to thank you for your contribution to the 17th St.Gallen International Breast Cancer Conference. It is our great pleasure to see so many delegates come together every two years to learn about the newest developments in treatment of women with early breast cancer and take part in the unique St.Gallen International Breast Cancer Consensus Session.

Thank you for being with us and a special thank to our faculty members, panelists and sponsors for their valuable contribution to this conference!

 

Highlight of the conference

In case you missed the conference, take the opportunity to find out more about the conference and it’s highlight, the St.Gallen International Consensus Session, in the interview of Congress Report with our St.Gallen Oncology Conferences board member, Prof. Walter Weber. Find out more here.

 

Save the date

The next St.Gallen International Breast Cancer Conference will take place from 15 – 18 March 2023. We look forward to welcoming you again in 2023!

 

St.Gallen Consensus

The virtual 17th St.Gallen International Breast Cancer Conference closed as usual with an update of the widely acknowledged St.Gallen International Breast Cancer Consensus on the optimal treatment of women with early breast cancer for the following two years. The consensus and its related scientific core issues are now online as a special article in the Annals of Oncology. You can find the manuscript here:

Customizing local and systemic therapies for women with early breast cancer: The St.Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

H.J. Burstein, G. Curigliano, B. Thürlimann, W.P. Weber, P. Poortmans, M. Regan, H.J. Senn, E.P. Winer, M. Gnant and Panelists of the St.Gallen Consensus Conference.

 

Webcasts

The webcasts of the scientific programme will be available here for conference participants for six months starting from Monday, 22 March 2021. This service is supported by an educational grant provided by Veracyte. Please note, that the consensus session is not included in the webcasts.

 

 

Thank you for your contribution. Looking forward to welcoming you again in 2023!

Your SG-BCC 2021 Organising Team

 

St.Gallen Oncology Conferences
c/o Tumor- and Breast Center ZeTuP
Rorschacherstrasse 150, 9006 St.Gallen/Switzerland
sgbcc@oncoconferences.ch
www.sg-bcc.org

chairs

 

Meet our chairs:

Conference founder and honorary chair
Prof. Dr. med. Hans-Joerg Senn, c/o Tumor and Breast Center ZeTuP St.Gallen / Switzerland

 

Conference co-chairs
Univ. Prof. Dr. Michael Gnant, Medical University of Vienna / Austria
Prof. Dr. med. Beat Thürlimann, Breast Centre, Kantonsspital St.Gallen / Switzerland

 

Scientific Programme-Chairpersons
Harold Burstein, Boston/MA, USA
Giuseppe Curigliano, Milano/Italy
Michael Gnant, Vienna/Austria
Meredith Regan, Boston/MA, USA
Hans-Jörg Senn, St.Gallen/Switzerland
Beat Thürlimann, St.Gallen/Switzerland
Walter Weber, Basel/Switzerland
Eric Winer, Boston/MA, USA

faculty members

 

Conflict of Interest Statements

All faculty members of the scientific programme have submitted a conflict-of-interest-statement.
The summary of all statements is available here

.

Aapro Matti, Genolier Cancer Centre, Genolier, Switzerland


Aebi Stefan, Tumorzentrum LUKS, Luzerner Kantonsspital, Lucerne, Switzerland


André Fabrice, Institut de Cancérologie Gustave Roussy, Villejuif, France


Barrios Carlos, Centro de Pesquisa em Oncologia, Hospital São Lucas, PUCRS, Porto Alegre, Brazil


Bergh Jonas, Karolinska Institutet and University Hospital, Stockholm, Sweden


Bonnefoi Herve, University of Bordeaux 2, Bordeaux, France


Bretel Morales Denisse, Oncosalud, Lima, Peru


Brucker Sara, Universitäts-Frauenklinik Tübingen, Tübingen, Germany


Burstein Harold, Dana-Farber Cancer Institute, Boston, United States


Cameron David, The University of Edinburgh, Edinburgh, United Kingdom


Cardoso Fatima, Champalimaud Cancer Center, Lisbon, Portugal


Carey Lisa, UNC – Lineberger Comprehensive Cancer Center, Chapel Hill, United States


Cescon Dave, Princess Margaret Hospital, Toronto, Canada


Chua Boon, Prince of Wales Hospital, Randwick, Australia


Ciruelos Eva, University Hospital 12 de Octubre, Madrid, Spain


Coates Alan, University of Sydney, Australia


Colleoni Marco, European Institute of Oncology, Milano, Italy


Cortes Javier, International Breast Cancer Center, Barcelona, Spain


Curigliano Giuseppe, European Institute of Oncology, Milano, Italy


Delaloge Suzette, Institut de Cancérologie Gustave Roussy, Villejuif, France


Denkert Carsten, Institut für Pathologie, Charité – Universitätsmedizin Berlin, Berlin, Germany


Dubsky Peter, Brustzentrum Hirslanden Klinik St. Anna, Lucerne, Switzerland


Ejlertsen Bent, DBCG Secretariat and Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark


Fitzal Florian, Medical University Vienna, Vienna, Austria


Francis Prudence, Peter McCallum Cancer Centre, Melbourne, Australia


Galimberti Viviana, European Institute of Oncology, Milano, Italy


Gamal Heba, National Cancer Institute, Cairo, Egypt


Garber Judy, Dana-Farber Cancer Institute, Boston, United States


Giordano Sharon, The University of Texas MD Anderson Cancer Center, Houston, United States


Gnant Michael, Medical University Vienna, Vienna, Austria


Gradishar William, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine,
Northwestern University, Chicago, United States


Gulluoglu Bahadir, Marmara University School Of Medicine, Istanbul, Turkey


Harbeck Nadia, Frauenkliniken Maistrasse-Innenstadt und Großhadern, Munich, Germany


Heil Jörg, Heidelberg University, Heidelberg, Germany


Huang Chiun-Sheng, National Taiwan University Hospital, Taipei, Taiwan


Huober Jens, Kantonsspital St.Gallen, St.Gallen, Switzerland


Ilbawi Andre, WHO Cancer Control Program, Switzerland


Jiang Zefei, 307 Hospital No.8, Beijing, China


Johnston Steven, Royal Marsden Hospital, London, United Kingdom


King Tari, Dana-Farber Cancer Institute, Boston, United States


Krop Ian, Dana-Farber Cancer Institute, Boston, United States


Lee Eun Sook, National Cancer Center, Goyang-si, Korea


Lin Nancy, Dana-Farber Cancer Institute, Boston, United States


Loi Sherene, Peter McCallum Cancer Centre, Melbourne, Australia


Loibl Sibylle, GBG Forschungs GmbH, Neu-Isenburg, Germany


Morrow Monica, Memorial Sloan-Kettering Cancer Center, New York, United States


Pagani Olivia, Institute of Oncology Southern Switzerland, Bellinzona, Switzerland


Partridge Ann, Dana-Farber Cancer Institute, Boston, United States


Piccart Martine, Institut Jules Bordet, Brussels, Belgium


Poortmans Philip, Iridium Kankernetwerk & University of Antwerp, Antwerp, Belgium


Prat Aleix, Hospital Clinic of Barcelona, Barcelona, Spain


Pusic Andrea, Brigham and Women’s Hospital, Boston, United States


Regan Meredith, Dana-Farber Cancer Institute, Boston, United States


Rubio Isabella, Clinica Universidad de Navarra, Madrid, Spain


Rugo Hope, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States


Rutgers Emiel, Netherlands Cancer Institute, Amsterdam, Netherlands


Sedlmayer Felix, Paracelsus Medical University, Salzburg, Austria


Semiglazov Vladimir, N.N.Petrov Research Institute of Oncology, St. Petersburg, Russian Federation


Shao Zhiming, Fudan University Cancer Hospital, Shanghai, China


Spanic Tanja, Europa Donna, Ljubljana, Slovenia


Tesarova Petra, Charles University Hospital and 1st medical faculty, Prague, Czech Republic


Thürlimann Beat, Kantonsspital St.Gallen, St.Gallen, Switzerland


Tjulandin Sergei, N.N. Blokhin Cancer Research Center, Moscow, Russian Federation


Toi Masakazu, Graduate School of Medicine Kyoto University, Kyoto City, Japan


Trudeau Maureen, University of Toronto, Toronto, Canada


Turner Nicholas, The Royal Marsden Hospital, London, United Kingdom


Tutt Andrew, Breast Cancer Now Research Centre, London, United Kingdom


Vaz Luis Ines, Institut de Cancérologie Gustave Roussy, Villejuif, France


Viale Giuseppe, Istituto Europeo di Oncologia, Milano, Italy


Watanabe Toru, Hamamatsu Oncology Center, Hamamatsu, Japan


Weber Walter, Klinik für Allgemeinchirurgie, Universitätsspital Basel, Basel, Switzerland


Winer Eric P., Dana-Farber Cancer Institute, Boston, United States


Xu Binghe, National Cancer Center, Beijing, China


subject to changes

 

 

conference programme

Accelerating access to innovation in early breast cancer

 

Browse through our scientific programme, read the awardees‘ contribution and find out more about the industry symposia, our virtual conference platform and all conference-related matters.

Download the final programme here

 

Thank you to all participants for being with us and a special thank to our faculty members and panelists for their valuable contribution to this conference!

the St.Gallen Consensus on the optimal Treatment of women with early breast cancer

 

The St.Gallen International Breast Cancer Conference 2021 closed as usual with an update of the widely acknowledged St.Gallen International Breast Cancer Consensus on the optimal Treatment of Women with early breast cancer.

In order to allow even more room for discussions on early breast cancer care, the 2021 Consensus Session took place on two days, 20 and 21 March 2021. For the first time ever, the consensus panel decided that they want to hear the questions of the audience directly, who made good use of the new Q&A Tool.

The list of all members of the St.Gallen 2021 International Breast Cancer Consensus panel can be found here.

 

Publication 2021

The consensus and its related scientific core issues are now available online in a special article of the Annals of Oncology:

Customizing local and systemic therapies for women with early breast cancer: The St.Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

H.J. Burstein, G. Curigliano, B. Thürlimann, W.P. Weber, P. Poortmans, M. Regan, H.J. Senn, E.P. Winer, M. Gnant and Panelists of the St.Gallen Consensus Conference.

 

Publications 2019:

Estimating the benefits of therapy for early-stage breast cancer: read the St.Gallen International Consensus Guidelines for the Primary therapy of early breast cancer 2019 here.

 

 

 

webcasts

 

The webcasts of the pre-recorded on-demand sessions and the live discussion sessions from 17 to 19 March 2021 are available to all delegates of the 17th St.Gallen International Breast Cancer Conference 2021. Please note, that the consensus session is not included in the webcasts.

> You can access the webcasts here!

 

The webcasts are exclusively supported by

 

Click on the links below to view the webcasts of the St.Gallen International Breast Cancer Conferences of the previous years:

certificate

 

CME Points & Certificate of Attendance
The Certificate of Attendance including the CME credits will be sent to all participants by e-mail upon completion of the online survey. The link to the online survey will be provided by e-mail.

Full conference participation counts for 10 CME credit points (17 – 21 March 2021) – credits will be assigned per day of participation. Please find the breakdown of ECMEC®s per day below:
17.03.2021 – 2.00 CME credit points
18.03.2021 – 2.00 CME credit points
19.03.2021 – 2.00 CME credit points
20.03.2021 – 2.00 CME credit points
21.03.2021 – 2.00 CME credit points

award winners

 

St.Gallen International Breast Cancer Award Winner 2021

The Foundation Council of “St.Gallen Oncology Conferences“ (SONK) proudly announces the recipient of the “St.Gallen International Breast Cancer Award 2021“, which was delivered during the 17th St.Gallen International Breast Cancer Conference, 17-21 March, 2021 to:

Prof. Philip Poortmans
Iridium Netwerk & University of Antwerp, Belgium

> find out more about Prof. Philip Poortmans


 

 

ESO Umberto Veronesi Memorial Award Winner 2021
 

Fatima Cardoso, MD
Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal
President, ABC Global Alliance

> find out more about MD Fatima Cardoso

abstracts

 

accepted abstracts

We are pleased to publish herewith the list of all accepted abstracts:

>List of abstracts

 

book of abstracts

All abstracts have been published in an electronic supplement issue to the journal “The Breast” by Elsevier Publishers. The abstracts are Open Access on both the journal website and on ScienceDirect.

 

best poster awards 2021

We proudly present the three winners of the St.Gallen Oncology Conferences Best Poster Awards 2021:

 

We thank our partners and sponsors who support the 17th St.Gallen International Breast Cancer Conference.

co-operating partner

sponsoring partner

promotional partner

satellite symposia programme

 

Wednesday, 17 March 2021
10.30 – 12.00 (CET)Answer in CME (Lilly)
12.15 – 13.45 (CET)F. Hoffmann-La Roche
16.45 – 18.15 (CET)Pfizer Oncology
 
Thursday, 18 March 2021
12.45 – 13.45 (CET)Seagen
16.45 – 18.45 (CET)Daiichi Sankyo Europe GmbH
18.30 – 19.30 (CET)NOVARTIS
 
Friday, 19 March 2021
12.45 – 13.45 (CET)Exact Sciences
16.45 – 18.15 (CET)PIERRE FABRE

 

 

Wednesday, 17 March 2021

 

 


10.30 – 12.00 (CET)

When Recurrence is in the Cards: Recognizing and Addressing Risk in Patients with HR-positive, HER2-negative Early Breast Cancer

Faculty:
William J. Gradishar, USA
Nadia Harbeck, Germany

  • Welcome and Introductions
  • Identifying Which Way the Deck is Stacked for Patients with Early Breast Cancer
  • Showing Your Cards When it Comes to Risk Assessment for Early Breast Cancer
  • Addressing the Cards Dealt with Evolving Treatment for Early Breast Cancer
  • Using the Cards Up Your Sleeve to Optimize Treatment for Early Breast Cancer
  • Q&A
  • Take Home Learnings

> back to top

 

 

12.15 – 13.45 (CET)

Advancing care for patients with early breast cancer
  • 12:15–12:20 Welcome and introduction
    Dr Giampaolo Bianchini, Italy
  • 12:20–12:40 Making optimal treatment decisions for patients with HER2-positive eBC
    Dr Giampaolo Bianchini, Italy
  • 12:40–12:50 Improving treatment beyond efficacy for patients with HER2-positive eBC
    Prof. Christian Jackisch, Germany
  • 12:50–13:10 The role of cancer immunotherapy in the treatment of patients with early triple negative breast cancer
    Prof. Peter Schmid, UK
  • 13:10–13:20 Beyond efficacy: Patient-reported outcomes from cancer immunotherapy trials in early triple negative breast cancer
    Dr Elizabeth Mittendorf, USA
  • 13:20–13:35 Panel discussion
    Moderated by Dr Giampaolo Bianchini, Italy
  • 13:35–13:40 Dr Giampaolo Bianchini

> back to top

 

 

16.45 – 18.15 (CET)

 

The value of experience: Improving patient outcomes in a new era of clinical evidence
  • Defining the moment: Treatment discussions in HR+/HER2- breast cancer
    Giuseppe Curigliano, Italy
  • The era of genetic testing: Treatment selection for patients with germline BRCA-mutated locally advanced or metastatic breast cancer
    Paul Cottu, France
  • Q&A
    Giuseppe Curigliano, Italy
    Paul Cottu, France
  • The time is now: Harnessing the value of real-world evidence in clinical decision making
    Winson Cheung, Canada
    Paul Cottu, France
  • Q&A
    Winson Cheung, Canada
    Paul Cottu, France
  • Looking forward: Future directions of treatment in HR+/HER2- metastatic breast cancer
    Giuseppe Curigliano, Italy

> back to top

 

 

Thursday, 18 March 2021

 

 

12.45 – 13.45 (CET)

Experts exploring HER2CLIMB

Faculty:
Dr Stephanie Sutherland, UK (Chair)
Prof. Sibylle Loibl, Germany
Dr Mafalda Oliveira, Spain

  • Understanding the HER2CLIMB study design
  • Exploring the data: HER2CLIMB efficacy and safety
  • Diving Deeper: HER2CLIMB subgroups
  • Live Q&A session
  • Short closing statement

> back to top

 

 

16.45 – 18.15 (CET)

Next-generation antibody-drug conjugates: New hope for HER2
  • Opening remarks
    Jean-Yves Pierga, France (Co-Chair)
  • The innovative mode of action of next-generation antibody-drug conjugates (ADCs)
    Matthias Peipp, Germany
  • Next-generation ADCs in the treatment of advanced breast cancer (ABC)
    Rupert Bartsch, Austria
  • New hope for HER2: Early intervention in HER2-positive breast cancer
    Sibylle Loibl, Germany
  • New recommendations for HER2: Guideline update
    Fatima Cardoso, Portugal
  • New paradigm for HER2: Place of the next-generation ADCs in the treatment landscape
    Panel Discussion and Q&A
    All speakers
  • Closing remarks
    Nadia Harbeck, Germany (Co-Chair)

> back to top

 

 

18.30 – 19.30 (CET)

Reimagining Treatment of HR+, HER2– EBC

Speakers:
Aleix Prat, Spain
Giuseppe Curigliano, Italy

  • Opening remarks
  • Recurrence Risk: A Clinical or Genomic Assessment?
  • Who May Benefit from CDK4/6i in the EBC Setting?
  • What Might the Future Look Like in EBC?
  • Live Q&A session
  • Closing remarks

> back to top

 

 

Friday, 19 March 2021

 

 
 

12.45 – 13.45 (CET)

Confidence in treatment decisions for HR+, HER2- early breast cancer patients

Chair:
Mark Harries, UK

  • Recent landmark RxPONDER results: impact on treatment decisions for node-positive patients
    Suzette Delaloge, France
  • An integrated view of the latest clinical evidence
    Giuseppe Curigliano, Italy
  • What will we do on Monday morning?
    Moderated by Mark Harries with the entire panel
  • Patient cases and discussion

> back to top

 

 

16.45 – 18.15 (CET)


EXTEND HER PROTECTION AGAINST BREAST CANCER RECURRENCES

Patient cases in HER2+ early breast cancer

  • Welcome and introduction
    Prof. S. Loibl (Chair), Germany
  • Practice update | Evolving concepts in HER2+/HR+ early breast cancer
    Prof. S. Loibl
  • Managing risk | A patient with node-positive HER2+/HR+ breast cancer after adjuvant treatment
    Prof. R. Bartsch, Austria
  • Check the narrative | Preventing recurrence in a patient after neoadjuvant therapy
    Dr. J. O’Shaughnessy, USA
  • HER experience | Understanding the patient’s perspective
    Panel discussion
    All faculty joined by Ms Laure Guéroult-Accolas, Patients en réseau
  • Live Q&A and close
    Prof. S. Loibl

> back to top

 

impressions 

 

Thank you for sharing so many photos of your virtual participation at the 17th St.Gallen International Breast Cancer Conference 2021! Have a look at the many vivid photos and the colorful impressions we have captured for you:

 

SG-BCC impressions

 

You can’t find your photo? Send it to sgbcc@oncoconferences.ch and we will post it.

contact

 

Scientific programme and faculty

St. Gallen Oncology Conferences (SONK)
c/o Tumor and Breast Center ZeTuP
Rorschacherstrasse 150
9006 St.Gallen / Switzerland
+41 71 243 00 32
info@oncoconferences.ch

 

Industrial exhibition, satellite symposia, registration, hotel accommodation, networking programme, abstract submission

Mondial Congress & Events
Mondial GmbH & Co. KG
Operngasse 20b, 1040 Vienna / Austria
+43 1 588 04 0
bcc21@mondial-congress.com

Newsletter abonnieren